How IGF-1 LR3 Affects Blood Glucose

IGF-1 LR3 lowers glucose through insulin-like signalling:

1. GLUT4 translocation: IGF-1 activates its own receptor and cross-activates the insulin receptor at high free concentrations, driving GLUT4 transporters to the muscle plasma membrane within about 10 minutes and pulling glucose into muscle (Bilan et al., 1992).
2. Prolonged exposure: LR3 resists the binding proteins, so it circulates free and active for an extended window. Unlike a fast insulin spike, the glucose-lowering pressure persists for hours, which is why hypoglycaemia can arrive late, overnight, or after cardio.
3. Blunted rescue: IGF-1-induced hypoglycaemia does not trigger glucagon counter-regulation the way insulin hypoglycaemia does, and glucose recovery is significantly delayed (Kerr et al., 1993). The body's rescue hormone barely fires.
4. Fasted injection is the danger: with no carbohydrate on board, the insulin-like glucose drawdown has nothing to buffer it.

Acute (per injection):

• Blood glucose falls within the first 1-4 hours, front-loaded after injection
• A fasted or post-cardio injection produces the steepest, most dangerous drop
• Symptomatic hypoglycaemia (shakiness, sweating, confusion) can appear hours after dosing

Human proxy data: mecasermin (licensed rhIGF-1) caused hypoglycaemia in 47% of patients in its pivotal trial, with several seizures or losses of consciousness, in supervised patients dosing within 20 minutes of a meal (FDA Increlex data). Bodybuilders use higher doses, unsupervised.

Chronic: with sustained supraphysiological IGF-1, fasting glucose tends to climb as insulin resistance develops (the acromegaly pattern), even though acute injections lower it.

Threshold: symptomatic hypoglycaemia below 3.5 mmol/L (63 mg/dL) is a hard stop. IGF-1 lows are slower to recover than insulin lows.

Baseline: fasting glucose before starting, alongside fasting insulin and HbA1c.

During use:

• Keep a glucometer on hand and check if you feel hypoglycaemic, especially in the hours after injection and overnight
• Fasting glucose every 1-2 weeks on a 4-6 week cycle
• A rising fasting glucose (above 6.1 mmol/L or more than 20% over baseline on two draws) signals developing insulin resistance

Critical safety rule: never inject LR3 fasted, and keep fast-acting carbohydrates (glucose tablets, juice) within reach the entire time the peptide is active. Treat a low early and do not assume you can ride it out.

Prevent the low: eat carbohydrate within 20-30 minutes of injection, mirroring the mecasermin label requirement. Inject post-workout when muscle glucose uptake is already primed and food is planned.

Treat a low fast and hard: because glucagon barely fires, oral fast carbs are your first line, and you may need more than you would for an insulin low. Anyone using LR3 should not dose alone if inexperienced.

The stack danger: combining LR3 with exogenous insulin and GH layers three glucose-lowering or glucose-confounding vectors. When GH's hyperglycaemic effect fades but LR3 is still active, the combined glucose drop is unmasked, which is when late hypoglycaemia happens.

If fasting glucose climbs over the cycle: this is the chronic insulin-resistance direction. Reassess dose, carbohydrate timing, and whether to stop.